Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Zoonotic influenza pandemics can cause substantial morbidity and mortality, especially in children. The present study evaluated the immunogenicity and safety of six formulations of an MF59-adjuvanted H5N1 vaccine (aH5N1). In this phase 2, dose-ranging study, children aged 6 months to
Fields of Study & Subjects
Influenza Virus Research Studies
Bacterial Infections and Vaccines
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Vaccine
- Volume
- 80
- Pages
- 128504–128504
- Publication date
- 26 March 2026
- Language
- EN